--- canonical_url: https://www.stockexpertai.com/earnings/dgx last_updated: 2026-05-09T13:44:20.441Z --- # Quest Diagnostics Incorporated (DGX) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T13:44:20.016Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $187.39 (▼ -1.81%) | fmp:quote | | Market Cap | $20.7B | fmp:profile | | 52w range | $164.65 – $213.50 | fmp:quote | | Earnings | Tue 28 Jul | fmp:earnings-history | | EPS estimate | $2.83 (+8% YoY) | fmp:earnings-estimate | | Revenue estimate | $3.0B | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | A- (overall 4/5) | fmp:ratings | | Analyst median target | $220 (+17.4% upside) | fmp:price-target-consensus | | MoonshotScore | 40/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Quest Diagnostics Incorporated — Q4 FY2026 Expectations Q4 consensus: revenue $3.0B^{[FMP est]}, EPS $2.83^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** A- · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 40 = MoonshotScore 40^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (4 metrics) ### 1. Revenue Growth Quest Diagnostics achieved revenue growth of over 9%, driven by clinical innovations, expansion into new clinical areas, and collaborations. > "During the first quarter, we grew revenues over 9%, almost entirely from organic revenue growth on broad-based demand for our clinical innovations, expansion into new clinical areas and collaborations with elite health care and consumer health organizations." > — James Davis, Chairman, Chief Executive Officer and President, Investor Focus · Q1 FY2026 ### 2. Eps Growth Quest Diagnostics grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from the deployment of automation and AI across its operations. > "In addition, we grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI across our operations both in and outside our labs." > — James Davis, Chairman, Chief Executive Officer and President, Investor Focus · Q1 FY2026 ### 3. Ai Customer Service Quest Diagnostics boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses. > "As one example, we boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses." > — James Davis, Chairman, Chief Executive Officer and President, Investor Focus · Q1 FY2026 ### 4. Ai Companion Engagement Patients have engaged Quest AI Companion approximately 350,000 times since Quest Diagnostics rolled it out to users of its MyQuest app in the first quarter. > "Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our MyQuest app in the first quarter." > — James Davis, Chairman, Chief Executive Officer and President, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 2.0 | weak | Q1 vs Q2: moderate growth (+4.9%) | | Gross Margin | 3.0 | weak | Q1: average margin (32.5%) | | Operating Leverage | 1.0 | weak | op margin average (13.8%) | | Cash Runway | 10.0 | strong | FCF strong ($0.2B FCF, covers CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 38.8 weak momentum, 50d below | | News Sentiment | 5.0 | medium | majority buy (50%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +17.4% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 39 | | Klarman | neutral | value · target upside +17.4% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +17.4% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Strong - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 38.8 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $197 — hisse %5.0 altında — kısa vadeli direnç - **200d MA:** $187 — hisse %0.3 üstünde — uzun vadeli destek - **Volume (10d):** -9% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $2.62 | $2.57 | BEAT | -4.4% | | Q3 FY25 | $2.60 | $2.50 | BEAT | -1.9% | | Q4 FY25 | $2.42 | $2.36 | BEAT | +1.9% | | Q1 FY26 | $2.50 | $2.37 | +5.5% EPS | -0.5% | Q1 (April 21, 2026): EPS $2.50 vs $2.37 est^[FMP], +5.5% beat. D+1 movement: -0.5%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $2.83 + CapEx discipline** Threshold: EPS > $2.83^{[FMP est]}. Target: Break above median target $220^{[FMP target]}; high target $235^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $2.83 + CapEx < $114.0M** Threshold: EPS ≈ $2.83^{[FMP est]}, Q4 CapEx < $114.0M^[FMP]. Target: Consolidation in the band between current $187^[FMP] and median $220^[FMP]. ### Scenario C · Miss **EPS < $2.75 or CapEx ≥ $114.0M** Threshold: EPS < $2.75^{[FMP est×0.97]}. Target: Current $187^[FMP] below SMA200 $187, if rejection continues, $159^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.50 vs $2.37 beat^[FMP], stock -0.5% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $114.0M^{[FMP cashflow]}. Q1 op margin 13.8%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $220 (+17.4% upside vs current $187) - **High / Low:** $235 / $210 - **Buy / Hold / Sell:** 9 / 9 / 0 - **Analyst count:** 9 (last quarter), 47 all-time ## Additional Transcript Insights ### 1. revenue_growth **Claim:** Quest Diagnostics achieved revenue growth of over 9%, driven by clinical innovations, expansion into new clinical areas, and collaborations. **Evidence (transcript):** "During the first quarter, we grew revenues over 9%, almost entirely from organic revenue growth on broad-based demand for our clinical innovations, expansion into new clinical areas and collaborations with elite health care and consumer health organizations." **Numbers:** 9% ### 2. eps_growth **Claim:** Quest Diagnostics grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from the deployment of automation and AI across its operations. **Evidence (transcript):** "In addition, we grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI across our operations both in and outside our labs." **Numbers:** 13% ### 3. 2026_guidance_increase **Claim:** Quest Diagnostics is raising its revenue and EPS guidance for the year given its strong first quarter momentum and continued strategic focus. **Evidence (transcript):** "Given our strong first quarter momentum and continued strategic focus, we are raising our revenue and EPS guidance for the year." **Numbers:** — ### 4. hospital_channel_growth **Claim:** Quest Diagnostics grew revenues at a double-digit rate in the hospital channel with the majority of this growth coming from its collaborative lab solutions for Corewell Health, a leading health system in Michigan. **Evidence (transcript):** "In the hospital channel, we grew revenues at a double-digit rate with the majority of this growth coming from our collaborative lab solutions for Corewell Health, a leading health system in Michigan." **Numbers:** — ### 5. ai_customer_service **Claim:** Quest Diagnostics boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses. **Evidence (transcript):** "As one example, we boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses." **Numbers:** 40% ### 6. ai_companion_engagement **Claim:** Patients have engaged Quest AI Companion approximately 350,000 times since Quest Diagnostics rolled it out to users of its MyQuest app in the first quarter. **Evidence (transcript):** "Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our MyQuest app in the first quarter." **Numbers:** 350,000 --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*